215 results on '"Lindegaard, H"'
Search Results
2. POS0052 FIVE-YEAR FOLLOW-UP OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON RADIOGRAPHIC DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION - THE IMAGINE-MORE STUDY
3. POS0010 PROTEOMIC LANDSCAPE OF SYNOVIAL TISSUE IN RHEUMATOID ARTHRITIS AND DETERMINANTS OF SYNOVIAL HISTOLOGICAL PATHOTYPES
4. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial
5. Galectin‐3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti‐CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity
6. CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL
7. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis
8. OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL
9. POS0550 LONG TERM EFFICACY OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON DISEASE ACTIVITY, MRI INFLAMMATION AND PHYSICAL FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION: FIVE YEAR FOLLOW-UP OF THE IMAGINE RA-COHORT
10. AB1354 ULTRASOUND JOINT EXAMINATION BY AN AUTOMATED SYSTEM VERSUS BY A RHEUMATOLOGIST – FROM A PATIENT PERSPECTIVE
11. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial
12. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals
13. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.
14. POS0377 FIBROCYTES IN EARLY AND LONGSTANDING RHEUMATOID ARTHRITIS: A 6-MONTH TRIAL WITH REPEATED SYNOVIAL BIOPSY, IMAGING, AND LUNG FUNCTION TEST
15. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
16. THE IMPACT OF AN ULTRASOUND ATLAS FOR SCORING SALIVARY GLANDS IN PRIMARY SJOGREN'S SYNDROME: A RELIABILITY EXERCISE
17. CHARACTERISTICS OF PRIMARY SJOGREN'S SYNDROME INCLUDING ULTRASOUND FINDINGS OF THE SALIVARY GLANDS, ESSDAI AND ESSPRI
18. FRI0019 MRI INFLAMMATION, DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT ARE MORE EFFECTIVELY REDUCED BY ESCALATION TO BIOLOGICS COMPARED TO CSDMARD-ESCALATION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY: SECONDARY ANALYSES OF THE IMAGINE-RA TRIAL
19. SAT0130 TREAT-TO-TARGET STRATEGY OF >8.000 PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DOES SMOKING AFFECT ACHIEVEMENT OF REMISSION ON METHOTREXATE AND TIME TO START OF FIRST BIOLOGIC? RESULTS FROM THE NATIONWIDE DANISH DANBIO REGISTRY
20. OP0312 THE IMPACT OF AN ULTRASOUND ATLAS FOR SCORING SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME: A RELIABILITY EXERCISE
21. SAT0233 CHARACTERISTICS OF PRIMARY SJÖGREN’S SYNDROME INCLUDING ULTRASOUND FINDINGS OF THE SALIVARY GLANDS, ESSDAI AND ESSPRI
22. AB0209 PREDICTORS OF ACHIEVING STRINGENT REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY
23. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
24. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry
25. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study
26. Circulating Surfactant Protein D is Decreased in Early Rheumatoid Arthritis: A 1-year Prospective Study
27. MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION
28. Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study
29. Low field dedicated magnetic resonance imaging in untreated rheumatoid arthritis of recent onset
30. One year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. An observational DANBIO study
31. Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across europe
32. Safety, feasibility and tolerability of performing consecutive minimal invasive ultrasound-guided synovial biopsy procedures on the same wrist in a prospective rheumatoid arthritis study
33. Risk of revision, prosthetic joint infection and death following total hip or knee arthroplasty in patients with rheumatoid arthritis – a nationwide cohort study from denmark
34. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial
35. OP0149 An mri guided treat-to-target strategy in rheumatoid arthritis patients in clinical remission improved mri inflammation but not damage progression – results from the imagine-ra randomised controlled trial
36. OP0278-HPR Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across europe
37. THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry
38. OP0018 The value of adding mri to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-ra randomised controlled trial
39. FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study
40. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials
41. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care
42. FIVE-YEAR FOLLOW-UP OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON RADIOGRAPHIC DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION - THE IMAGINEMORE STUDY.
43. Changes in multi-biomarker disease activity (MBDA) score correlate with changes in established disease activity measurements in patients with early RA from the opera study
44. Health anxiety by proxy: A new concept with important treatmentimplications
45. SAT0045 11 years' follow-up of a danish 2-year treat-to-target randomized controlled trial in patients with early rheumatoid arthritis: baseline predictors of functional and radiographic outcomes
46. THU0072 Risk of revision, prosthetic joint infection and death following total hip or knee arthroplasty in patients with rheumatoid arthritis – a nationwide cohort study from denmark
47. FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry
48. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)
49. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)
50. Effect of Methotrexate and Intra-Articular Betamethasone with or Without Additional Cyclosporine on Magnetic Resonance Imaging (MRI)-Determined Inflammatory and Destructive Changes in Very Early Rheumatoid Arthritis – Results from a 24-Months' Randomised Double Blind Placebo Controlled Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.